Mo. Planned Parenthood Clinic Resumes Abortion Services

After a three-month hiatus, a Planned Parenthood clinic in Columbia, Mo., has begun offering abortion services again, the Columbia Daily Tribune reports. The clinic stopped performing surgical abortions and administering medical abortions because no physician was available, Peter Brownlie, executive director of Planned Parenthood of Kansas and Mid-Missouri, said…

More J&J Drugs Pulled from Shelves

WASHINGTON (MedPage Today) — More batches of over-the-counter (OTC) products are being voluntarily recalled by Johnson & Johnson subsidiary McNeil Consumer Healthcare — this time including two products for kids.

High-Deductible Health Insurance Results in Less Care (CME/CE)

(MedPage Today) — Lower-income families in health plans with high deductibles are more likely than higher-income families to delay or skip medical care in order to avoid paying for it out-of-pocket, a new study found.

‘Positive Outcome’ Bias Found in Peer Review (CME/CE)

(MedPage Today) — One reason that so-called negative studies often fail to be published may be “positive-outcome bias” in peer review, said researchers who conducted a randomized trial.

More J&J Drugs Pulled from Shelves

WASHINGTON (MedPage Today) — More batches of over-the-counter (OTC) products are being voluntarily recalled by Johnson & Johnson subsidiary McNeil Consumer Healthcare — this time including two products for kids.

FTC/TDF tablet reduces HIV infection among high-risk individuals: iPrEx study

In a finding with the potential to fundamentally change strategies to slow the global HIV epidemic, a new study called iPrEx shows that individuals at high risk for HIV infection who took a single daily tablet containing two widely used HIV medications, emtricitabine and tenofovir (FTC/TDF), experienced an average of 43.8% fewer HIV infections than [...]

GCM supports iPrEx Study to prevent HIV infection among MSM

The Global Campaign for Microbicides (GCM) welcomes today’s news from the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Disease (NIAID) of the US National Institutes of Health (NIH) and the Gladstone Institutes of the University of California, San Francisco that daily use of oral emtricitabine (FTC) with tenofovir (TDF) in [...]

Important queries about PrEP, iPrEx trial for HIV infection

The results of the iPrEx PrEP effectiveness trial of once-daily TDF/FTC (brand name Truvada) in gay men, transgender women and other men who have sex with men are a landmark in HIV prevention research.

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

In a significant advance for HIV prevention research, a clinical trial confirms that the same drugs used for treating HIV can also help prevent HIV infection in the first place.

iPrEx study: PrEP reduces HIV infection risk among gay, bisexual men

A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men.